Michael Goldbrunner

1.4k total citations · 1 hit paper
9 papers, 943 citations indexed

About

Michael Goldbrunner is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Michael Goldbrunner has authored 9 papers receiving a total of 943 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Michael Goldbrunner's work include Lung Cancer Treatments and Mutations (3 papers), PI3K/AKT/mTOR signaling in cancer (2 papers) and Cancer therapeutics and mechanisms (1 paper). Michael Goldbrunner is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), PI3K/AKT/mTOR signaling in cancer (2 papers) and Cancer therapeutics and mechanisms (1 paper). Michael Goldbrunner collaborates with scholars based in Germany, Switzerland and Hong Kong. Michael Goldbrunner's co-authors include Erwin von Angerer, Howard A. Burris, Stefan S. De Buck, José Baselga, Qinhua Ru, Jordi Rodón, Diana C. Birle, David Demanse, Malte Peters and Jaap Verweij and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Medicinal Chemistry and Investigational New Drugs.

In The Last Decade

Michael Goldbrunner

9 papers receiving 923 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

2011 550 citations Johanna C. Bendell, Jordi Rodón et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Goldbrunner Germany	7	572	268	239	205	155	9	943
Vito Guagnano Switzerland	16	896 1.6×	380 1.4×	343 1.4×	135 0.7×	104 0.7×	30	1.4k
Timothy J. Guzi United States	16	792 1.4×	538 2.0×	261 1.1×	258 1.3×	91 0.6×	31	1.4k
Ronald E. Savage United States	20	632 1.1×	341 1.3×	150 0.6×	270 1.3×	136 0.9×	43	1.3k
Masao Iwata Japan	11	976 1.7×	294 1.1×	147 0.6×	209 1.0×	68 0.4×	13	1.6k
Martin Pass United Kingdom	16	551 1.0×	250 0.9×	212 0.9×	97 0.5×	62 0.4×	31	873
Mark S. Albom United States	19	470 0.8×	325 1.2×	404 1.7×	190 0.9×	75 0.5×	34	983
Chris Liang United States	13	581 1.0×	463 1.7×	239 1.0×	479 2.3×	60 0.4×	36	1.1k
Jean Cui United States	10	518 0.9×	407 1.5×	231 1.0×	427 2.1×	41 0.3×	18	1.0k
Wells S. Brown United States	15	552 1.0×	266 1.0×	89 0.4×	139 0.7×	98 0.6×	24	895
Teeru Bihani United States	14	530 0.9×	388 1.4×	86 0.4×	353 1.7×	63 0.4×	27	1.1k

Countries citing papers authored by Michael Goldbrunner

Since Specialization

Citations

This map shows the geographic impact of Michael Goldbrunner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Goldbrunner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Goldbrunner more than expected).

Fields of papers citing papers by Michael Goldbrunner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Goldbrunner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Goldbrunner. The network helps show where Michael Goldbrunner may publish in the future.

Co-authorship network of co-authors of Michael Goldbrunner

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Goldbrunner. A scholar is included among the top collaborators of Michael Goldbrunner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Goldbrunner. Michael Goldbrunner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Wong, Raymond, İrfan Yavaşoğlu, Mohamed A. Yassin, et al.. (2022). Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE. Blood Advances. 7(17). 4773–4781. 4 indexed citations

2.

Sharma, Sunil, Elisabeth G.E. de Vries, Jeffrey R. Infante, et al.. (2013). Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investigational New Drugs. 32(1). 135–144. 39 indexed citations

3.

Bendell, Johanna C., Jordi Rodón, Howard A. Burris, et al.. (2011). Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 30(3). 282–290. 550 indexed citations breakdown →

4.

Baselga, José, Maja J. De Jonge, Jordi Rodón, et al.. (2010). A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3003–3003. 42 indexed citations

5.

Sharma, Shringi, Elisabeth G.E. de Vries, J. R. Infante, et al.. (2008). Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3538–3538. 19 indexed citations

6.

Schlingensiepen, Reimar, Michael Goldbrunner, Piotr Jachimczak, et al.. (2005). Intracerebral and Intrathecal Infusion of the TGF-β2-Specific Antisense Phosphorothioate Oligonucleotide AP 12009 in Rabbits and Primates: Toxicology and Safety. Oligonucleotides. 15(2). 94–104. 50 indexed citations

7.

Jachimczak, Piotr, et al.. (2003). 229 Suppression of TGF-beta2 in pancreatic cancer by the antisense oligonucleotide ap 12009: preclinical efficacy data as basis for clinical studies. European Journal of Cancer Supplements. 1(5). S71–S71. 1 indexed citations

8.

Gastpar, Robert, Michael Goldbrunner, Doris Marko, & Erwin von Angerer. (1998). Methoxy-Substituted 3-Formyl-2-phenylindoles Inhibit Tubulin Polymerization. Journal of Medicinal Chemistry. 41(25). 4965–4972. 109 indexed citations

9.

Goldbrunner, Michael, et al.. (1997). Inhibition of Tubulin Polymerization by 5,6-Dihydroindolo[2,1-a]isoquinoline Derivatives. Journal of Medicinal Chemistry. 40(22). 3524–3533. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact